anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to medicine and cellular biotechnology, and can be used for producing a substance which suppresses malignant cells in acute lymphoblastic leukemia (ALL), which can be used in treating oncohematological and autoimmune diseases. In order to produce a biologically active substance, chicken heads are electrically stimulated at 100-120 V at an amperage of 3-5 A for 3-5 seconds, and blood is then harvested and incubated. Serum is then isolated. A polypeptide fraction having a molecular mass of 850-1200 Da is then isolated from the serum. The obtained polypeptide fraction is lyophilized and sterilized by means of irradiation in an electron linear accelerator, with a dose of 28-32 kHz. The technical result consists in suppressing malignant cells in acute lymphoblastic leukemia in a patient's body (providing a cytotoxic effect) and in decreasing hematological and immunological toxicity and the risk of the severe complications observed in the case of antitumor chemotherapy by using a substance produced via the proposed method, and further consists in simplifying and reducing the cost of the method by means of using accessible raw materials.
This study is a single-group, open-label (name of study drug is known to patients), multicenter study to evaluate the safety and efficacy/treatment response of paliperidone palmitate administered for 25 weeks as once-monthly injections to Chinese patients with schizophrenia who previously received treatment with oral antipsychotic medications. A target of 353 patients (inpatients or outpatients) with schizophrenia will be enrolled in the study and will receive injections of study drug (paliperidone palmitate) on Days 1 and 8, and thereafter at a monthly flexible dose, based on patients' tolerability and/or efficacy. The study will consist of a screening period of up to 1 week before treatment, a 25-week treatment period, and a follow-up period approximately 30 days after the last injection of study drug. Upon meeting the entry criteria for the study, patients will receive a total of 8 intramuscular (IM) injections of paliperidone palmitate during the treatment period as follows: 150 mg equivalent (eq) on Day 1, 100 mg eq on Day 8, and subsequent monthly IM injections with a flexible dose range of 75-150 mg eq. If the patient reports any signs or symptoms of worsening of schizophrenia, the investigator may prescribe a rescue medication (quick-relief or fast-acting medications that usually work right away to relieve symptoms) such as lorazepam (an antianxiety drug) to control agitation, irritability, restlessness, and hostility. Safety will be monitored throughout the study.
The present invention relates to a new application of a pulmonary surfactant in the field of preparing medicine. The pulmonary surfactant has the effects on lowering alveolar surface tension, reducing work of breathing, keeping pulmonary alveolus dry, etc. and has the function of immunological regulation for protecting alveolar cells from the direct damage of harmful substances. The pulmonary surfactant is used for treating diseases such as pneumonitis, asthma, adult or children's respiratory distress syndrome, newborns' syndrome of meconium aspiration, old people's chronic bronchitis, pneumonectasis, etc. of respiratory systems, etc. The present invention adopts the administration mode by using oxygen for driving atomized aspiration.
The present invention relates to use of a licorice extract for enhancing activity of Nrf-2, a method for preparing the same, and a cosmetic composition comprising the same. More specifically, the method for preparing the composition for enhancing activity of Nrf2 comprises the following steps: extracting the Nrf2 activating composition, comprising a licorice extract as an active ingredient, and licorice with an alcohol solvent having 1-4 carbon atoms; obtaining powder by freezing and drying the extract; obtaining a fraction from the powder by using water and ethyl acetate; and obtaining a water fraction from the fraction. According to the present invention, the cosmetic composition has an effect of enhancing ARE activity related to Nrf-2. When the cosmetic composition is applied to skin, homeostasis of the skin, exposed to the outside all the time and suffering from stress, is maintained. The cosmetic composition has an excellent effect of preventing skin aging caused by active oxygen. Therefore, a hypoallergic, skin-friendly, and antiaging cosmetic product in an advanced concept can be developed.
Background: Interest in post-coronavirus disease 2019 (COVID-19) syndrome following COVID-19 infection has been increasing. Maintaining quality of life (QoL) is vital for airline crews because they work in a special environment, where they are responsible for the passengers' safety. This study aims to closely investigate factors affecting the QoL of airline crews, including post-COVID-19 syndrome. Methods: This study was designed as a cross-sectional survey, comprising 167 crews. Findings: Age-specific significant differences were observed in social, overall, and total QoL scores. The physical domain QoL was significantly higher in the cockpit crews than that in the cabin crews. Significant differences were found in psychological and overall QoL depending on years of continuous service. Social domain and environmental QoL were lower in those who had no symptoms after being diagnosed with COVID-19 than in those who were symptomatic. Among the participants, 4.2% had post-COVID-19 syndrome, indicating significant differences in the physical domain, depending on whether they exhibit post-COVID-19 syndrome. Conclusion: It is urgent to develop measures to increase the QoL of airline crews, investigate post-COVID-19 syndrome before returning to work, and develop strategies to manage it. Application to practice: The QoL among airline crews differed not only by the demographic characteristics of the participants but also by the presence of symptoms during COVID-19 diagnosis and post-COVID-19 syndrome. Higher QoL among airline crews is associated with the safety of both airline crews and passengers. Therefore, it is necessary to establish a systematic management protocol for airline crews returning to work after following COVID-19 infection.
The recommended starting dose is one to two drops of levobunolol hydrochloride ophthalmic solution 0.5% in the affected eye(s) once a day. Typical dosing with levobunolol hydrochloride ophthalmic solution 0.25% is one to two drops twice daily. In patients with more severe or uncontrolled glaucoma, levobunolol hydrochloride ophthalmic solution 0.5% can be administered b.i.d. As with any new medication, carefully monitoring of patients is advised.

Dosages above one drop of levobunolol hydrochloride ophthalmic solution 0.5% b.i.d. are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrin and/or epinephrine, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted. Patients should not typically use two or more topical ophthalmic beta-adrenergic blocking agents simultaneously.
Risk Summary

Based on animal data with irinotecan HCl and the mechanism of action of ONIVYDE, ONIVYDE can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women. Embryotoxicity and teratogenicity were observed following treatment with irinotecan HCl, at doses resulting in irinotecan exposures lower than those achieved with ONIVYDE 70 mg/m2 in humans, administered to pregnant rats and rabbits during organogenesis [see Data]. Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

No animal studies have been conducted to evaluate the effect of irinotecan liposome on reproduction and fetal development; however, studies have been conducted with irinotecan HCl. Irinotecan crosses the placenta of rats following intravenous administration. Intravenous administration of irinotecan at a dose of 6 mg/kg/day to rats and rabbits during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses. In separate studies in rats, this dose resulted in an irinotecan exposure of approximately 0.002 times the exposure of irinotecan based on area under the curve (AUC) in patients administered ONIVYDE at the 70 mg/m2 dose. Administration of irinotecan HCl resulted in structural abnormalities and growth delays in rats at doses greater than 1.2 mg/kg/day (approximately 0.0002 times the clinical exposure to irinotecan in ONIVYDE based on AUC). Teratogenic effects included a variety of external, visceral, and skeletal abnormalities. Irinotecan HCl administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring.
FIELD: medicine, pharmacy, cosmetology. SUBSTANCE: composition comprises piroxicam taken at an effective anti-inflammatory amount and tetrahydroxypropylethylenediamine at amount sufficient for solubilization of piroxicam and C 2-6 -ethylene glycol or a mixture of these glycols. Glycols are taken at sufficient amount to prevent stickiness of the composition and provide its wetting. The composition has, wt.-%: carbomer 0.2-2; C 2-4 -alkanol 30-60 and water - up to 100%. Invention claims also a method of solubilization of piroxicam that includes its mixing with tetrahydroxypropylethylenediamine taken at amount sufficient for the solubilization. Invention claims also the composition containing piroxicam and tetrahydroxypropyl- -ethylenediamine taken at amount sufficient for solubilization of piroxicam. Invention ensures to obtain the more stable piroxicam-containing gel compositions which do not form spherules and salt on perspired skin. They are transparent. EFFECT: improved quality and properties of compositions. 18 cl, 2 tbl
Genetic variants can affect gene expression by altering the level of N6-methyladenosine (m6A) modifications. A better understanding of the association of these genetic variants with susceptibility to cervical cancer (CC) can promote advances in disease screening and treatment. Genome-wide identification of m6A-associated functional SNPs for CC was performed using the TCGA and JENGER databases, incorporating the data from RNA-seq and MeRIP-seq. The screened risk-associated SNP rs1059288 (A>G), which is located in the 3' UTR of TAPBP, was further validated in a case-control study involving 921 cases and 1077 controls. The results revealed a significant association between rs1059288 and the risk of CC (OR 1.48, 95% CI 1.13-1.92). Mechanistically, the presence of the risk G allele of rs1059288 was associated with increased m6A modification of TAPBP compared with the A allele. This modification was facilitated by the m6A methyltransferase METTL14 and the reading protein YTHDF2. Immunohistochemical staining of tissue microarrays containing 61 CC and 45 normal tissues showed an overexpression of TAPBP in CC. Furthermore, the upregulation of TAPBP promoted the growth and migration of CC cells as well as tumor-forming ability, inhibited apoptosis, and conferred increased resistance to commonly used chemotherapeutic drugs such as bleomycin, cisplatin, and doxorubicin. Knockdown of TAPBP inhibited the JAK/STAT/MICB signaling pathway in CC cells and upregulated certain immune genes including ISG15, IRF3, PTPN6, and HLA-A. These findings offer insights into the involvement of genetic variations in TAPBP in the development and progression of CC.
BACKGROUND: To date, there is insufficient research on whether shift work and night work increase the risk of experiencing headaches and migraines.
OBJECTIVES: This study aimed to evaluate the potential association between shift work, night shift work, and headache/migraine.
METHODS: We conducted a thorough search of the PubMed, Embase, and Web of Science databases up until October 2023 to identify relevant studies. Our inclusion criteria focused on observational studies that investigated the association between shift work exposure and headache/migraine outcomes. We extracted adjusted risk estimates from each study and calculated pooled odds ratios using either fixed or random-effects models. Our methodology followed the Meta-Analysis Group guidelines for observational studies in epidemiology. To ensure accuracy and consistency, two investigators independently reviewed the retrieved records and extracted data based on the predefined inclusion criteria.
RESULTS: This meta-analysis included a total of seven studies involving 422,869 participants. The pooled analysis revealed a significant association between shift work and an increased risk of headaches (HR = 1.32, 95% CI: 1.15-1.52, P < 0.001). Specifically, individuals working night shifts had a 44% higher risk of developing headaches (HR = 1.44, 95% CI: 1.09-1.90, P = 0.011). Furthermore, shift work was also found to be associated with a higher incidence of migraines (HR = 1.63, 95% CI: 1.27-2.08, P < 0.001). Interestingly, night shift work was associated with a decreased incidence of migraines (HR = 0.74, 95% CI: 0.57-0.96, P = 0.024).
CONCLUSION: Our study found a noteworthy association between shift work/night work and the occurrence of headaches and migraines. However, it is important to note that our study does not establish a causal relationship. Future research should investigate potential common vulnerability factors, such as genetics or health behaviors. This knowledge can help inform the implementation of preventive measures and interventions to mitigate the health risks associated with shift work.
<P>PROBLEM TO BE SOLVED: To obtain an oral composition capable of treating and preventing hypertension, capable of ameliorating symptoms accompanied with the hypertension, such as vertigo, ear noise, headache, shortness of breath, numbness of hand and foot, flush of face, perspiration of palm, fever, general physical weariness, decrease in physical strength, giddiness, stiffness in shoulders, joint and muscular pain, poor falling asleep and sleeplessness, anxiety, solitary feeling, decrease in concentration, and decrease in eagerness, and safe even when administered for a long period.  <P>SOLUTION: The subject ameliorating agent for the hypertension is formed by mixing Piper longum thereinto. An angiotensin activity inhibitor is formed by the same manner. The agent for the hypertension which is safe, even when administered for the long period, and has enough efficacy is obtained by this method. Further, a medicine, a functional food, a food, a supplement, and the like, are obtained by using the same.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The training interventions will last 6 months. The intensity of physical activity will be determined as a percentage of maximum heart rate (HRmax), assessed based on a fitness test (Chester Step Test), using data from mobile devices monitoring physical activity. Cognitive function (CF) levels, and the concentrations of GDNF, BDNF, and CLU, as well as the Chester Step Test, will be evaluated twice: once at baseline and once after the training programs. Blood samples for measuring neurotrophin and CLU levels will be collected in the morning, after an overnight fast (approximately 12 hours since the last meal). The concentrations of neurotrophins and CLU will be measured using the ELISA method. CF will be assessed using standardized and validated neuropsychological tests.

Expected Outcomes: Greater improvement in CF in the dance group compared to the resistance training and control groups, with higher levels of BDNF, GDNF, and CLU in the dance group.
End-stage renal disease is a chronic disease requiring treatment with dialysis or renal transplantation. Patients require an adequate vascular access for hemodialysis (HD). Autologous arteriovenous fistula (AVF) is gold standard to maintain vascular access for HD . Vascular access-related complications can lead to patient morbidity and reduction of patient quality of life.The complication rate related to permanent HD vascular access remains relatively high and access related problems are responsible for 50% of the hospitalization of dialysis patients. Secondary failures are not rare and in need of adequate attention and care. Once the AVF has been placed. It is recommended that serial monitoring of the AVF should be done for long term effective function. Delays in preventing complications may lead to AVF dysfunction. However, little is known about the factors determining long term prognosis of an AVF.

Primary patency (intervention-free access survival) was defined as the interval from time of access placement to any intervention designed to maintain or reestablish patency or to access thrombosis or the time of measurement of patency. Assisted primary patency (thrombosis-free access survival) was defined as the interval from time of access placement to access thrombosis or time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a patent access. Secondary patency (access survival until abandonment) was defined as the interval from time of access placement to access abandonment or time of measurement of patency, including intervening manipulations (surgical or endovascular interventions) designed to reestablish the functionality of thrombosed access .

In patients having chronic renal failure (CRF), several changes occur in bone metabolism due to the development of secondary hyperparathyroidism. There are increased calcium and phosphate release from bones to the blood, causing the deposition of calcium and phosphate in the intima-media layer of arterial wall and eventuating vascular calcification in these patients. The deposition of these electrolytes increases the risk of cerebrovascular and coronary complications as well. Thus, a decrease in the quality of fistula occurs in these tracts utilized frequently at the arteriovenous fistula (AVF) operations.
Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
This is a prospective pilot study to determine MUNE and CMAP values in a population of adults with SMA, assess how these electrophysiologic parameters change over time, and explore how well these parameters correlates with other outcome measures in SMA, including functional scales (SMAFRS and SF-36) and muscle strength (by MMT, MVICT, 6 minute walk test, time to climb 4 stairs and handheld myometry). The study was started in 2006 with 4 visits. It was initially intended to measure baseline and variability of values at baseline, 6 months, 10-14 months, and 20-24 months to better characterize the disease and to validate measurements as suitable outcome measures to be used in future therapeutic trials on adults. Individuals who do not take nusinersen would continue on this visit plan.

With the addition of the FDA approved drug nusinersen for SMA we would like to follow people who are receiving that treatment more frequently. The visits will fall in relationship to their treatment doses. Those patients who are receiving nusinersen will come in at a baseline visit that will be1 to 6 weeks prior to first treatment. Then they would follow-up one to 2.5 weeks after each treatment dosing that happens quarterly after the initial loading dose. There will be 10 visits over 3 years. The visits will occur at baseline, 2, 6, 10, 14, 18, 22, 26, 30, and 34 months. These additional visits will allow for better uniform monitoring of the response to treatment and resubmission to insurance providers. Additional long term data will be collected from interested/available patients every 2-3 years up to a max of fifteen years. Being followed long term would add 4-6 visits over 12 years. If subjects completed the study course in the past and are now starting nusinersen (SPINRAZA), those individuals are able to enroll again.

A total of 100 people with SMA will be enrolled in this trial. This will allow for two cohorts of people with SMA; those receiving treatment and those not receiving treatment.

Control participants will only come to a baseline visit and the only tests that will be completed are the EMG Measures (MUNE, CMAP, decomposition EMG) and EIM. There will be no further testing for those participants. This visit will take approximately 30-60 minutes. A total of 40 control participants are being recruited for this study.
Interactions between different bacteria play an important role in biofilm development during primary colonization of the human tooth surface. Well studied examples of such interactions include the receptor polysaccharide (RPS)-mediated interactions between viridans group streptococci and other oral bacteria including type 2 fimbriated Actinomyces naeslundii. Previous studies have resulted in the identification of different structural, antigenic and molecular types of RPS on the streptococci that initiate colonization of the tooth surface. This information provides the basis for the current protocol, which addresses a number of important questions involving the nature of the commensal relationship that exists between biofilm-forming bacteria and the host. For example: (1) How many types of RPS are produced by the resident flora of an individual at any one time? (2) Does the resident population of RPS-producing clones change over the lifetime of the host? (3) Do individuals produce secretory antibodies against bacterial RPS, and if so, does this drive a change in the antigenic type of RPS produced? (3) When and how do infants acquire RPS-producing bacteria, before or after tooth eruption? To address these questions, we wish to collect and analyze samples of early dental plaque from the members of individual families. The collection of such samples will be accomplished by gently rubbing exposed tooth surfaces with a sterile cotton swab. Adult volunteers will also be asked to provide small samples of saliva, which will be assayed for the presence of specific anti-RPS antibodies. The sampling procedures proposed in this protocol do not present any significant risk to either adult or infant volunteers. The information gained from these studies, although not directly beneficial to these individuals, is expected to provide important insights into the commensal relationship that exists between biofilm-forming bacteria and the host. This in turn will contribute to an improved understanding of variables associated with the maintenance of oral health and the initiation of disease.
The research was planned as a randomized controlled trial, which is a quantitative study. Participants will be divided into 2 groups as control and exercise groups by simple randomization method. The individuals in the control group of the study will not be given any exercise program after surgery. A home exercise program created with Dynamic Neuromuscular Stabilization exercises after surgery will be applied to the individuals in the intervention group. Data collection will be carried out through an online survey. The scales and forms to be used before and after the treatment are respectively: 1. Oswestry Low Back Pain Disability Questionnaire 2. International Physical Activity Questionnaire (Short Form) 3. Questionnaire for Fear of Daily Living Activities The questionnaires will be uploaded to the Google Forms database and the participants will be accessed via e-mail or mobile phone applications. . They will be asked to fill out the questionnaires before starting the post-surgical exercise program and the exercise program will be explained practically before discharge. The exercises will be planned 3 times a week and for 8 weeks.